Akero Therapeutics ((AKRO)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akero Therapeutics is conducting a Phase 3 study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis. The study aims to assess the safety and effectiveness of Efruxifermin (EFX) in treating patients with NASH/MASH and fibrosis stages 2 or 3. This research is significant as it targets a condition with limited treatment options, potentially offering a new therapeutic avenue.
The study tests Efruxifermin, a drug administered via subcutaneous injection, in two dosages (28 mg and 50 mg) against a placebo. Efruxifermin is designed to treat liver fibrosis in patients with NASH/MASH, aiming to improve liver health and function.
This interventional study follows a randomized, parallel assignment model with quadruple masking (blinding participants, care providers, investigators, and outcomes assessors) to ensure unbiased results. The primary purpose is treatment-focused, aiming to establish Efruxifermin’s efficacy and safety.
The study began on December 1, 2023, and is currently recruiting participants. The last update was submitted on August 18, 2025. These dates are crucial as they mark the study’s progress and ongoing data collection, which investors should monitor for future developments.
The update on this study could positively impact Akero Therapeutics’ stock performance, as successful results may enhance investor confidence and position the company favorably in the competitive NASH treatment market. Investors should also consider the broader industry context, where advancements in NASH treatments are highly anticipated.
The study is ongoing, with further details available on the ClinicalTrials portal.